A proposed class action filed just days ago is shaking the generic drug industry — and millions of heart patients across America may be affected. The Glenmark carvedilol lawsuit, filed August 4, 2026, in the U.S. District Court for the Eastern District of Washington, alleges that Glenmark Pharmaceuticals Inc. USA sold a generic version of the heart medication carvedilol (brand name Coreg) contaminated with a probable human carcinogen at levels exceeding FDA safety limits. With nearly 733,000 bottles already recalled and the complaint spanning 139 pages of detailed allegations, this case is rapidly emerging as one of the most significant nitrosamine drug contamination lawsuits of 2026 — and it arrives at a moment when Glenmark is already facing heightened legal scrutiny after reaching a $29.6 million multistate settlement in July 2026 over separate price-fixing conspiracy allegations involving generic drugs.
What Is the Glenmark Carvedilol Lawsuit?
Washington resident Sharon Carroll filed the proposed class action against Glenmark Pharmaceuticals Inc. USA on August 4, 2026, alleging the company sold generic carvedilol tainted with the chemical compound N-Nitroso-Carvedilol I — a substance classified as a probable human carcinogen. Carroll purchased Glenmark carvedilol four times between March 2024 and July 2025 using prescriptions tied to NDC codes 68462-0164-05 and 68462-0163-05, both of which were later included in Glenmark’s recalls. The suit seeks reimbursement of purchase and replacement costs on behalf of a nationwide class of consumers who unknowingly received the contaminated medication.
The 139-page complaint asserts that Glenmark’s generic carvedilol lacked the same safety profile, strength, quality, and purity as brand-name Coreg — a legally significant claim, because generic drugs are required by law to be equivalent to their brand-name counterparts. The Glenmark carvedilol lawsuit further charges that the company failed to manufacture the drug in a current Good Manufacturing Practice (cGMP)-compliant manner, rendering the products both adulterated and misbranded under federal law. For patients relying on this medication to manage life-threatening heart conditions, those are not minor technical violations — they go to the core of what patients were promised when they filled their prescriptions. If you believe you were harmed by a contaminated pharmaceutical product, understanding how damages are calculated is a critical first step — a medical malpractice calculator can help you begin estimating potential compensation for defective drug injuries.
The Recall: Scope, Timeline, and FDA Classification
The recall that underlies the Glenmark carvedilol lawsuit is substantial in scale. According to FDA enforcement records, the recall covers 732,960 bottles across multiple strengths and package sizes, including 3.125 mg, 12.5 mg, and 25 mg tablets manufactured by Glenmark Pharmaceuticals Ltd. in India and distributed throughout the United States. Glenmark voluntarily initiated the recall on August 6 and 7, 2025, with the FDA confirming a Class II classification on August 12 and 14, 2025.
A Class II recall designation means that use of the product may cause temporary or medically reversible adverse health effects, and that the probability of serious health consequences is considered remote — but the long-term cancer risk associated with nitrosamine exposure complicates that framing significantly. Regulators consider nitrosamines to be high potency mutagenic carcinogens, meaning they can cause DNA damage with lasting consequences. The FDA has established an acceptable intake limit of 4.0 ppm for N-Nitroso-Carvedilol I; Glenmark’s product allegedly exceeded that threshold. Glenmark itself attributed the recall to its failure to conduct adequate nitrosamine risk assessments — a process the FDA has been requiring of all drug manufacturers in the years since the landmark valsartan contamination crisis first brought nitrosamines into the public spotlight. Notably, the FDA updated its nitrosamine drug substance-related impurities guidance on July 24, 2026, expanding recommendations with additional API-specific entries including mitapivat and dalbavancin-related NDSRIs, underscoring just how actively regulators are working to close the gaps that have allowed contamination events like this one to occur.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.